open access
English
The gastrointestinal and hepatic lapatinib-associated adverse effects
open access
Abstract
Its efficacy in the treatment of metastatic and locally advanced breast cancer limited to HER2 overexpressing
tumors was confirmed in several phase II and phase III clinical trials. In ongoing trial, activity
of lapatinib in combination with chemotherapy ± trastuzumab in adjuvant setting is investigated. Several
toxicities are specific to lapatinib. The most common are diarrhea and skin toxicities (rash). Hepatic toxicity
are rare but can be life threatening. These side effects may limit prolonged treatment. The aim of this article
is to review the incidence and mechanism of gastrointestinal and hepatic lapatinib-associated adverse
effects and also provide recommendation how to manage them in clinical practice.
Abstract
Its efficacy in the treatment of metastatic and locally advanced breast cancer limited to HER2 overexpressing
tumors was confirmed in several phase II and phase III clinical trials. In ongoing trial, activity
of lapatinib in combination with chemotherapy ± trastuzumab in adjuvant setting is investigated. Several
toxicities are specific to lapatinib. The most common are diarrhea and skin toxicities (rash). Hepatic toxicity
are rare but can be life threatening. These side effects may limit prolonged treatment. The aim of this article
is to review the incidence and mechanism of gastrointestinal and hepatic lapatinib-associated adverse
effects and also provide recommendation how to manage them in clinical practice.
Keywords
toxicity, gastrointestinal events, hepatic events, lapatinib
About this articleTitle
The gastrointestinal and hepatic lapatinib-associated adverse effects
Journal
Issue
Article type
Review paper
Pages
113-118
Published online
2012-08-29
Page views
479
Article views/downloads
1387
Bibliographic record
Onkol. Prak. Klin 2012;8(3):113-118.
Keywords
toxicity
gastrointestinal events
hepatic events
lapatinib
Authors
Aleksandra Łacko